Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Rheumatoid Arthritis/Systemic Lupus Erthyematosus | Access and Reimbursement | US | 2016
Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are chronic and, in many cases, debilitating diseases requiring lifelong treatment. Costs associated with biologic treatment for RA…
Evolution of the Rheumatoid Arthritis Treatment Paradigm | Physician & Payer Forum | EU5 | 2015
The entrenched positioning of biologics (in particular, tumor necrosis factor-alpha [TNF-alpha] inhibitors) to treat moderate-to-severe rheumatoid arthritis (RA) has generated a multi-billion-…
Market Access Opportunities and Challenges in Rheumatoid Arthritis | Physician & Payer Forum | EU5 | 2015
A Survey of Rheumatologists and Interviews with Payers in the EU5 Rheumatoid arthritis (RA) is a complex autoimmune condition characterized by chronic and progressive joint inflammation that…